Skip Navigation LinksHome > Published Ahead-of-Print > Effects of Exercise during Adjuvant Chemotherapy on Breast C...
Medicine & Science in Sports & Exercise:
doi: 10.1249/MSS.0000000000000297
Original Investigation: PDF Only

Effects of Exercise during Adjuvant Chemotherapy on Breast Cancer Outcomes.

Courneya, Kerry S.; Segal, Roanne J.; McKenzie, Donald C.; Dong, Huiru; Gelmon, Karen; Friedenreich, Christine M.; Yasui, Yutaka; Reid, Robert D.; Crawford, Jennifer J.; Mackey, John R.

Published Ahead-of-Print
Collapse Box

Abstract

Introduction: Observational studies suggest that physical activity after a breast cancer diagnosis is associated with improved cancer outcomes; however, no randomized data are available. Here, we report an exploratory follow-up of cancer outcomes from the Supervised Trial of Aerobic versus Resistance Training (START).

Methods: The START Trial was a Canadian multicenter trial that randomized 242 breast cancer patients between 2003-2005 to usual care (n = 82), supervised aerobic (n = 78) or resistance (n = 82) exercise during chemotherapy. The primary endpoint for this exploratory analysis was disease-free survival (DFS). Secondary endpoints were overall survival (OS), distant disease-free survival (DDFS), and recurrence-free interval (RFI). The two exercise arms were combined for analysis (n = 160) and selected subgroups were explored.

Results: After a median follow-up of 89 months, there were 25/160 (15.6%) DFS events in the exercise groups and 18/82 (22.0%) in the control group. Eight-year DFS was 82.7% for the exercise groups compared with 75.6% for the control group (Hazard ratio [HR]= 0.68, 95% CI = 0.37-1.24; log-rank p = 0.21). Slightly stronger effects were observed for OS (HR = 0.60, 95% CI = 0.27 to 1.33; log-rank p = 0.21), DDFS (HR = 0.62, 95% CI = 0.32 to 1.19; log-rank p = 0.15), and RFI (HR = 0.58, 95% CI = 0.30 to 1.11; Gray's p = 0.095). Subgroup analyses suggested potentially stronger exercise effects on DFS for women who were overweight/obese (HR = 0.59, 95% CI = 0.27-1.27), had stage II/III cancer (HR = 0.61, 95% CI = 0.31-1.20), ER positive tumors (HR = 0.58, 95% CI = 0.26-1.29), HER2 positive tumors (HR = 0.21, 95% CI = 0.04-1.02), received taxane-based chemotherapies (HR = 0.46, 95% CI = 0.19-1.15), and >= 85% of their planned chemotherapy (HR = 0.50, 95% CI = 0.25-1.01).

Conclusions: This exploratory follow-up of the START Trial provides the first randomized data to suggest that adding exercise to standard chemotherapy may improve breast cancer outcomes. A definitive phase III trial is warranted.

(C) 2014 American College of Sports Medicine

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us